Macrocyclic Kinase Inhibitors Efficacy Specificity Trade-off
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved protein kinase inhibitors to effectively treat diseases associated with aberrant protein kinase activity, such as cancers, inflammatory diseases, and autoimmune disorders, as current treatments may have limitations in efficacy or specificity.
Innovation Solution
Development of macrocyclic compounds that bind to protein kinases, modulating their activity, and their use in pharmaceutical compositions and kits to treat or prevent proliferative, genetic, hematological, neurological, and metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current protein kinase inhibitors are used, then treatment is provided for diseases associated with aberrant kinase activity, but efficacy and specificity are limited
Solution Approach 1:
The patent employs parameter changes by modifying chemical structure parameters of kinase inhibitors, specifically developing macrocyclic compounds with distinct structural features (14-membered macrocyclic ring, specific heteroatom arrangements) to achieve improved binding affinity and selectivity for target kinases, thereby resolving the contradiction between efficacy and specificity
Solution Approach 2:
The invention utilizes composite material principles by creating macrocyclic compounds that combine multiple functional groups and structural elements (heteroatoms, aromatic rings, linker moieties) within a single molecular framework, enabling simultaneous optimization of efficacy through enhanced target binding and specificity through selective interaction with kinase active sites
2Reliability
If current protein kinase inhibitors are used, then treatment is provided for diseases associated with aberrant kinase activity, but limitations in efficacy or specificity remain
Solution Approach 1:
The patent applies segmentation by dividing the macrocyclic compound into distinct functional segments or moieties, including heteroatom-containing groups, aromatic rings, and linker structures, each contributing specific properties to the overall molecule. This modular approach enables systematic optimization of treatment effectiveness while managing molecular complexity through structured design
Solution Approach 2:
The invention demonstrates universality through macrocyclic compounds designed with multiple functional capabilities within a single molecular structure, enabling interaction with various kinase targets while maintaining a unified structural framework. This multi-functionality approach improves treatment effectiveness across different disease contexts without proportionally increasing complexity
Data Source
AI summary
The present disclosure provides macrocyclic compounds of Formula (I). The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.